LinkedIn co-founder Reid Hoffman has teamed up with Siddhartha Mukherjee, renowned cancer researcher and author of The Emperor of All Maladies, to establish a groundbreaking startup, Manas AI. This innovative company focuses on using artificial intelligence to accelerate drug discovery, particularly targeting breast, prostate, and lymphoma cancers.
The startup has secured US$24.6 million in seed funding, with backing from Hoffman himself and venture capital firms General Catalyst and Greylock. While this is a substantial investment, it is significantly smaller than the colossal funding other companies raised in the AI drug discovery space.
Competing with larger players in AI drug discovery
Manas AI’s US$24.6 million seed round starkly contrasts its competitors’ financial muscle. For instance, Xaira launched with an astounding $1 billion in initial funding last year, claiming to be ready to begin drug development. Similarly, Treeline Biosciences, another AI-driven drug discovery company, raised $422 million in 2023, as reported by Endpoints News.
Despite the smaller funding round, Manas AI’s approach sets it apart. The company aims to design molecules using advanced AI models and validate their potential in a wet lab environment. By combining AI capabilities with traditional lab testing, Manas AI hopes to streamline the drug discovery process and make it more efficient.
Leveraging Microsoft’s cloud technology and expertise
Manas AI will rely heavily on Microsoft’s cloud computing platform, Azure, to power its research. The partnership also involves utilising Microsoft’s expertise in artificial intelligence to develop new medicines. Hoffman, who has strong ties to Microsoft—stemming from its acquisition of LinkedIn in 2016—emphasised the role of technology in transforming drug discovery during a recent presentation of his book Superagency.
NEW: Reid Hoffman raises $24.6M for AI-cancer research startup
— Healthcare AI Guy (@HealthcareAIGuy) January 27, 2025
Manas AI combines AI-driven molecular design and wet-lab biology to target cancer, starting with breast, prostate, and lymphoma, before expanding to other areas pic.twitter.com/iIglK2Bfi0
By integrating AI and cloud technology, Manas AI seeks to carve a niche in a rapidly evolving competitive industry. Hoffman and Mukherjee’s collaboration brings together expertise in technology, research, and healthcare, setting the stage for potentially groundbreaking advancements in treating cancer.
While Manas AI’s funding may be modest compared to its competitors, its unique approach and strategic partnerships position it as a promising player in the AI-driven drug discovery sector.
